↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

31 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Abatacept  27件: Abatacept; Abatacept injection; Bms 188667 (abatacept); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; Abatacept subcutaneous; Abatacept sc; Abatacept (aba);   D03203   2件: CD80, CD86   3件: Cell adhesion molecules (CAMs), Intestinal immune network for IgA production, Rheumatoid arthritis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 2   Adalimumab  51件: Adalimumab; Adalimumab injection [humira]; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Double-blind adalimumab; Etanercept or adalimumab; Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Open-label adalimumab; Open-labeladalimumabrescue; Sb5 (proposed biosimilar to adalimumab); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Adalimumab (40 mg); Adalimumab (d2e7); Adalimumab 40 mg eow or ew; Adalimumab and infliximab; Adalimumab injection; Adalimumab prn; Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Fitc-adalimumab; Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Ol adalimumab 40 mg; Start adalimumab in monotherapy; Treatment with adalimumab; Adalimumab 40 mg sc every other week; Adalimumab, etanercept, golimumab or infliximab; Gp2017 (adalimumab biosimilar);   D02597   1件: TNF   9件: Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 3   Alendronic acid  1件: Alendronic acid;   D00939
 D07119 
 1件: FDPS   1件: Terpenoid backbone biosynthesis   7件:
19,
41,
46,
50,
271,
274,
299
 4   Alfacalcidol  3件: Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alfacalcidol; Ibandronate+alfacalcidol+calcium;   D01518   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   6件:
41,
46,
49,
50,
96,
235
 5   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Kineret® (anakinra); Response to anakinra associated with methotrexate; Anakinra / kineret; Kineret® or anakinra;   D02934   2件: IL1R1, IL1R2   2件: Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 6   Baricitinib  3件: Baricitinib; Baricitinib, olumiant®; Tofacitinib/baricitinib;   D10308   2件: JAK1, JAK2   3件: Chemokine signaling pathway, JAK-STAT signaling pathway, Osteoclast differentiation   8件:
41,
46,
49,
50,
93,
107,
265,
325
 7   Bosentan  14件: Bosentan; Bosentan mylan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan group; Bosentan monohydrate; Sildenafil 20mg and bosentan 62.5mg; Bosentan administration; Bosentan and sildenafil; Bosentan monohydrat; Bosentan, ambrisentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil singly or in association with bosentan;   D01227
 D07538 
 2件: EDNRA, EDNRB   2件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction   10件:
13,
41,
47,
51,
84,
85,
86,
88,
210,
211
 8   Ciclosporin  7件: Ciclosporin; Ciclosporina; Ciclosporine; Aerolised liposomal ciclosporin a; Ciclosporin (ciclosporinium); Ciclosporin a; Ciclosporine, ciclosporina;   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   44件:
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 9   Cyclophosphamide  49件: Cyclophosphamide; Cyclophosphamide (drug); Cyclophosphamide and atg; Cyclophosphamide monohydrate; Cyclophosphamide/glatiramer acetate; Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Lenalidomide, dexamethasone and cyclophosphamide; Rituximab and cyclophosphamide iv; Prednisone, cyclophosphamide; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Cyclophosphamide-prednisone-azathioprine; Iv cyclophosphamide; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 50mg; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; Busulfan, cyclophosphamide, atg, gcsf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide post transplant; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; High-dose cyclophosphamide; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and steroids; Cyclophosphamide(ctx); Cyclophosphamide + pred; Cyclophosphamide, fludarabine; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 
 -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 10   Dotatate  6件: Dotatate; Dotatate pet-ct; 68ga-dotatate; 68ga-dotatate pet/ct; Cu-64 dotatate; Gallium-68 dotatate;   -   -   -   3件:
41,
75,
84
 11   Ethanol  14件: Endocannabinoid palmitoylethanolamide (pea); Palmitoylethanolamide; Treprostinil diethanolamine; Ut-15c (treprostinil diethanolamine); Ut-15c sr (treprostinil diethanolamine); Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; Ethanolamine; Ethanolamine oleate;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 12   Filgrastim  7件: Filgrastim; Pegfilgrastim; Ep2006 (filgrastim); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); Filgrastim (g-csf);   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   28件:
2,
6,
13,
16,
25,
26,
28,
34,
35,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
85,
96,
113,
164,
283,
284,
285,
331
 13   Gevokizumab  2件: Gevokizumab; Gevokizumab open-label;   D09911   1件: IL1B   3件: Cytokine-cytokine receptor interaction, MAPK signaling pathway, NOD-like receptor signaling pathway   4件:
41,
50,
56,
269
 14   Hydroxychloroquine  16件: Hydroxychloroquine; Hydroxychloroquine sulfate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Hydroxychloroquine (z0188); Hydroxychloroquine high; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Versus hydroxychloroquine; Hydroxychloroquine + prednisone; Sirolimus and hydroxychloroquine; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine sulphate;   D08050   -   -   18件:
13,
41,
46,
48,
49,
53,
56,
66,
84,
89,
90,
96,
222,
234,
254,
271,
298,
299
 15   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 16   Mavrilimumab  4件: Mavrilimumab; Mavrilimumab 100 mg; Mavrilimumab 150 mg; Mavrilimumab 30 mg;   D09930   1件: CSF2RA   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   2件:
41,
46
 17   Methotrexate  81件: Methotrexate; Intrathecal methotrexate; Methotrexate treatment; Mycophenolate mofetil,methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Bms-582949 and methotrexate; Certolizumab pegol + methotrexate (mtx); Cp-690,550 + methotrexate; Etanercept + methotrexate; Etanercept , methotrexate; Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Methotrexate and folic acid; Methotrexate lachema 5inj. sol; Etanercept, methotrexate, prednisolone; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Azathioprine or methotrexate; Early immunosuppressants (azathioprine, methotrexate); Methotrexate bellon; Methotrexate bellon 25mg/ml; Clobetasol propionate + methotrexate; Treatment with systemic therapy (methotrexate); Cyclosporin, methotrexate (gvhd prophylaxis);   D00142
 D02115 
 2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 18   Methylprednisolone  29件: Methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Infliximab, methylprednisolone, methotrexate; Methotrexate + methylprednisolone; Administration of rituximab and methylprednisolone; Methylprednisolone (mp); Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Intravenous methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 19   Naltrexone  5件: Naltrexone; Naltrexone hydrochloride; 4.5 mg naltrexone; Low dose naltrexone; Naltrexone-hcl;   D02095
 D05113 
 3件: OPRD1, OPRK1, OPRM1   2件: Morphine addiction, Neuroactive ligand-receptor interaction   11件:
6,
10,
13,
40,
41,
42,
43,
44,
45,
96,
97
 20   Nivolumab  1件: Nivolumab;   D10316   1件: PDCD1   3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway   10件:
13,
26,
41,
46,
49,
50,
51,
53,
96,
97
 21   Prednisolone  74件: Prednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methyloprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Peg-liposomal prednisolone sodium phosphate; Prednisolone sodium phosphate; Prednisone/prednisolone; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Intravenous methyl prednisolone; Methyl prednisolone; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Infliximab, methylprednisolone, methotrexate; Long-circulating liposomal prednisolone; Methotrexate + methylprednisolone; Methotrexate - etanercept - prednisolone arm; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; Corticosteroids (prednisone or prednisolone); Oral prednisolone; Administration of rituximab and methylprednisolone; Prednisolone and taper; Etanercept, methotrexate, prednisolone; Methylprednisolone (mp); Prednisolone + mabthera; Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Prednisone or prednisolone; Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Prednisolone 1mg tablets; Prednisolone 5mg tablet; Glucocorticoid (prednisone or prednisolone); Low dose prednisolone; Medium dose prednisolone; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Corticosteroid (prednisolone); Prednisolone sodium succinate; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisolone sodium metasulphobenzoate; Prednisolone tablets b.p. 5mg; Intravenous methylprednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 22   Prednisone  59件: Prednisone; Prednisone - azathioprine; Prednisone alone; Granulocyte-colony stimulating factor (g-csf) and prednisone; Prednisone/prednisolone; Prednisone acetate; Prednisone, cyclophosphamide; Over encapsulated prednisone; Prednisone and ustekinumab treatment; Prednisone capsules; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Prednisone (and methylprednisolone); 0 mg prednisone; 5 mg prednisone; Methylprednisone; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Rayos (delayed-release prednisone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide-prednisone-azathioprine; Oral prednisone 5mg; Prednisone discontinuation; Chinese herb prescription granule plus prednisone; Enalapril valsartan methylprednisone; Hormone (prednisone); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Prednisone + inhibace/cozaar; Prednisone and cyclophosphamide; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Glucocorticoid (prednisone or prednisolone); Hydroxychloroquine + prednisone; Azathioprine/prednisone; 5-asa, prednisone, azathioprine or remicade; 5-aminosalicylic acid(5-asa) and/or prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Prednisone 0,5 mg/kg orally on alternate days; Prednisone, fk506, mmf; Tacrolimus combined with prednisone; Prednisone acetate tablets; Oral prednisone; Sotatercept with prednisone boost; Prednisone and mycophenolate mofetil; Thalidomide, cyclophosphamide and prednisone;   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 23   Prednisone acetate  2件: Prednisone acetate; Prednisone acetate tablets;   D08416   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   6件:
35,
40,
41,
49,
162,
224
 24   Sarilumab  4件: Sarilumab; Sarilumab sar153191; Sarilumab sar153191 (regn88); Sarilumab 200 mg/1.14 ml subcutaneous solution [kevzara]_#1;   D10161   1件: IL6R   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   5件:
41,
46,
84,
107,
271
 25   Secukinumab  12件: Secukinumab; Secukinumab 150mg; Secukinumab 300mg; Secukinumab 300 mg, s.c.; Secukinumab (ain457); 150 mg double-blinded secukinumab; 150 mg open-label secukinumab; 300 mg double-blinded secukinumab; Ain457/secukinumab; Secukinumab (150 mg); Secukinumab (75 mg); Secukinumab 150 milligram [cosentyx];   D09967   1件: IL17A   2件: Cytokine-cytokine receptor interaction, Rheumatoid arthritis   7件:
13,
37,
41,
46,
160,
269,
271
 26   Sirukumab  3件: Sirukumab; Sirukumab 100 mg; Sirukumab 50 mg;   D10080   1件: IL6   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   2件:
41,
46
 27   Tocilizumab  26件: Tocilizumab; Tocilizumab injection; Tocilizumab (mra-sc); Corticoids+ tocilizumab 8mg/kg/4 weeks; Tocilizumab + glucocorticoids (gcs); Tocilizumab sc; Tocilizumab treatment; Abatacept, rituximab or tocilizumab; Decrease tocilizumab, abatacept; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab (actemra®); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab prefilled syringe; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Inn-tocilizumab; Tocilizumab infusion roacemtra (eu);   D02596   1件: IL6R   3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway   16件:
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331
 28   Triamcinolone  10件: Triamcinolone; Triamcinolone acetonide; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); Triamcinolone acetonide and normal saline solution; Bladder instillation with triamcinolone acetonide; Bladder instillation without triamcinolone acetonide; Bupivacaine & triamcinolone acetonide; Intra plexus triamcinolone and bupivicaine injection;   D00385
 D00983
 D00984
 D00985
 D06216 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   18件:
6,
10,
13,
35,
40,
41,
42,
43,
44,
45,
46,
56,
70,
90,
96,
97,
226,
298
 29   Upadacitinib  2件: Upadacitinib; Upadacitinib (abt-494);   D10994   1件: JAK1   1件: JAK-STAT signaling pathway   6件:
41,
46,
49,
96,
97,
271
 30   Ustekinumab  32件: Ustekinumab; Prednisone and ustekinumab treatment; Ustekinumab (approximately 6 mg/kg); Ustekinumab 90 milligram (mg); Ustekinumab iv; Ustekinumab sc; Ustekinumab 6 mg/kg; Ustekinumab 90 mg; Subcutaneous ustekinumab; Stelara (ustekinumab); Ustekinumab liquid in prefilled syringe; Ustekinumab 180 mg; Ustekinumab 45 mg; Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271
 31   Vitamin D  31件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Cholecalciferol, vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d3; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Vitamin d in arm b; Vitamin d 25(oh)d; Vitamin d3 400 iu; Vitamin d3 6000 iu; Vitamin d3 3000 ui daily; Vitamin d3 4000 ui daily; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; High-dose vitamin d (2000 iu per day); Standard-dose vitamin d (400iu per day); Vitamin d 100ug; Vitamin d 10ug; 25-hydroxyvitamin d3; Cholecalciferol (vitamin d3); D6-25-hydroxyvitamin d3; Ergocalciferol (vitamin d2); High-dose vitamin d3; Supplementation with vitamin d2/d3; Vitamin d oil; Vitamin d powder; Vitamin d2;   -   -   -   18件:
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299

先頭へ